XKRX
002720
Market cap67mUSD
Oct 08, Last price
4,270.00KRW
1D
-3.61%
1Q
23.59%
Jan 2017
13.87%
Name
Kukje Pharma Co Ltd
Chart & performance
P/E
15.86
P/S
0.51
EPS
269.27
Div yield, %
0.70%
Shrs. gr., 5y
-0.86%
Rev. gr., 5y
6.12%
Revenues
175.50b
+12.16%
Net income
5.70b
+9.46%
CFO
5.84b
+48.11%
Dividend
Mar 12, 202630 KRW/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
KUKJE PHARMA Co. Ltd. engages in the manufacture, sale, and distribution of pharmaceutical, cosmetics, and healthcare products. Its products include cephalosporins, penicillins, quinolones, aminoglycosides, macrolides, antibiotics, and antifungal and antiviral agents. The company was founded on July 27, 1959 and is headquartered in Seongnam, South Korea.
Key people
Tae Hun Nam
President, Chief Executive Officer, Director · since 2025
Seong Gyu Kim
Chief Operating Officer, Managing Director · since 2024
Hae Seong Choi
Assistant Managing Director · since 2024
Bo Seok Oh
Assistant Managing Director · since 2024
Yeong Gwan Kim
Managing Director · since 2024
Pil Seong Choi
Non-Executive Independent Director · since 2020
Jeong Su Jeon
Non-Executive Independent Director · since 2020
Ga Won Lee
Non-Executive Independent Director · since 2020
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||